Waldenstrom Macroglobulinemia: all 372 studies
Page 1 of 4. Open to participants first (63), then studies with results posted, then the rest; newest registration first within each.
- Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)Not yet recruitingNCT07882173Phase 2
- Teclistamab In Waldenstrom's MacroglobulinemiaNot yet recruitingNCT07791498Phase 2
- Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsNot yet recruitingNCT07766421Phase 3
- Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor TherapyNot yet recruitingNCT07711327
- A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 1
- A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingNCT07609862Phase 1/2
- Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK InhibitorsNot yet recruitingNCT07592481Not applicable
- Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)Not yet recruitingNCT07548450Phase 2
- BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.Not yet recruitingNCT07474961Phase 4
- Nemtabrutinib, Bortezomib, and Rituximab for WMNot yet recruitingNCT07464210Phase 2
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 4
- A Study of APG-3288 in Relapsed/Refractory Blood CancersRecruitingNCT07424833Phase 1
- ABBV-383 for the Treatment of Relapsed Refractory Waldenström MacroglobulinemiaRecruitingNCT07420959Phase 1/2
- A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström MacroglobulinemiaNot yet recruitingNCT07259122Phase 2
- Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaRecruitingNCT07249905Phase 1/2
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingNCT07231952Phase 2
- Watch and Wait or Worry and Wait in Indolent LymphomaEnrolling by invitationNCT07173790
- Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström MacroglobulinemiaNot yet recruitingNCT07169565Phase 1
- This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic ProcessRecruitingNCT07160270
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )RecruitingNCT07101328Phase 1
- A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaRecruitingNCT06986174Phase 2
- Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06980116Phase 1
- Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's MacroglobulinemiaNot yet recruitingNCT06942507Not applicable
- Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramRecruitingNCT06860880Not applicable
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesRecruitingNCT06708897Phase 1
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingNCT06561347Phase 2
- Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation SequencingRecruitingNCT06550427
- Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström MacroglobulinemiaNot yet recruitingNCT06547866Phase 2
- SynKIR-310 for Relapsed/Refractory B-NHLRecruitingNCT06544265Phase 1
- Epcoritamab in Previously Treated WMRecruitingNCT06510491Phase 2
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasRecruitingNCT06340737Phase 1
- Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
- Patients Treated in Real Life With VEnetoclax for WAldenström MacroglobulinemiaRecruitingNCT06200220
- Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT StudyRecruitingNCT06151730
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's MacroglobulinemiaRecruitingNCT05979948Phase 2
- Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WMRecruitingNCT05914662Phase 2
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell MalignanciesRecruitingNCT05780034Phase 1
- Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase InhibitorsRecruitingNCT05643235Not applicable
- Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaRecruitingNCT05640102
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaRecruitingNCT05602363Phase 1
- Study of SGR-1505 in Mature B-Cell NeoplasmsRecruitingNCT05544019Phase 1
- Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular LymphomaRecruitingNCT05326308
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT05131022Phase 1
- Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaRecruitingNCT05099471Phase 2
- Spanish Registry of Patients With IgM Monoclonal GammopathiesRecruitingNCT05093153
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
- Clinical Study of the Hyperviscosity Syndrome in Waldenström MacroglobulinemiaRecruitingNCT04898647Not applicable
- Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström MacroglobulinemiaRecruitingNCT04893564Not applicable
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingNCT04840602Phase 2
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT04830137Phase 1
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.RecruitingNCT04775745Phase 1
- Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)RecruitingNCT04728893Phase 2
- Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory HemopathiesNot yet recruitingNCT04702932
- Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's MacroglobulinaemiaRecruitingNCT04061512Phase 2/3
- R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's MacroglobulinemiaRecruitingNCT03697356Phase 2
- Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
- Registry of Older Patients With CancerRecruitingNCT01137825
- Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
- Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)RecruitingNCT00923507
- Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesTerminatedNCT05537766Phase 2Results posted
- Ibrutinib + Venetoclax in Untreated WMActive, not recruitingNCT04273139Phase 2Results posted
- Dasatinib In Waldenström MacroglobulinemiaTerminatedNCT04115059Phase 1Results posted
- A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)CompletedNCT04062448Phase 2Results posted
- A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)CompletedNCT04042376Phase 4Results posted
- Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK InhibitorsCompletedNCT03771157Early Phase 1Results posted
- Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's MacroglobulinemiaTerminatedNCT03679624Phase 2Results posted
- Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's MacroglobulinaemiaCompletedNCT03630042Phase 2Results posted
- Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom MacroglobulinemiaTerminatedNCT03506373Phase 2Results posted
- Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaCompletedNCT03364231Phase 2Results posted
- Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 2Results posted
- Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)CompletedNCT03332173Phase 2Results posted
- Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone LymphomaTerminatedNCT03269552Phase 2Results posted
- Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell TransplantationTerminatedNCT03246906Phase 2Results posted
- A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaTerminatedNCT03225716Phase 1Results posted
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell TransplantActive, not recruitingNCT03192397Phase 1/2Results posted
- A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström MacroglobulinemiaCompletedNCT03187262Phase 2Results posted
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell TransplantationCompletedNCT03133221Phase 2Results posted
- A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)CompletedNCT03053440Phase 3Results posted
- Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin LymphomaCompletedNCT03010358Phase 1/2Results posted
- Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme MalignanciesTerminatedNCT02991898Phase 2Results posted
- BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or LeukaemiaCompletedNCT02933320Phase 1/2Results posted
- Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström MacroglobulinemiaCompletedNCT02677324Phase 2Results posted
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)CompletedNCT02669017Phase 1Results posted
- Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome SequencingCompletedNCT02604511Phase 2Results posted
- Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy PatientsCompletedNCT02566265Phase 2Results posted
- Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström MacroglobulinemiaTerminatedNCT02439138Phase 2Results posted
- Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaCompletedNCT02400437Phase 2Results posted
- Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401CompletedNCT02363439Phase 1/2Results posted
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
- Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02339922Phase 2Results posted
- Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT02332980Phase 2Results posted
- Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaCompletedNCT02257242Phase 1Results posted
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
- Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell LymphomasCompletedNCT02213913Phase 1/2Results posted
- An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaActive, not recruitingNCT02180724Phase 2Results posted
- Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaCompletedNCT02165397Phase 3Results posted